Will you have Agranulocytosis with Gallbladder cancer metastatic - from FDA reports


Agranulocytosis is found among people with Gallbladder cancer metastatic, especially for people who are male, 60+ old, take medication Sorafenib and have High blood pressure. This study is created by eHealthMe based on reports of 10 people who have Gallbladder cancer metastatic from FDA, and is updated regularly.

What's eHealthMe?

eHealthMe is a health data analysis company based in Mountain View, California. eHealthMe monitors and analyzes the outcomes of drugs and supplements that are currently on the market. The results are readily available to health care professionals and consumers.

eHealthMe has released original studies on market drugs and worked with leading universities and institutions such as IBM, London Health Science Centre, Mayo Clinic, Northwestern University and VA. eHealthMe studies have now been referenced in over 500 peer-reviewed medical publications.

How we gather our data?

Healthcare data is obtained from a number of sources including the Food and Drug Administration (FDA). This information is aggregated and used to produce personalized reports that patients can reference.

The information that eHealthMe collects includes:

  • Side effects (including severity and how people recover from them)
  • Associated conditions or symptoms
  • Drug effectiveness
  • Demographic data regarding drug use

How the study uses the data?

The study is based on Agranulocytosis and Gallbladder cancer metastatic, and their synonyms.

What is Gallbladder cancer metastatic?

Gallbladder cancer metastatic (gallbladder cancer spreads to other part) (latest reports from 128 Gallbladder cancer metastatic patients)

What is Agranulocytosis?

Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection) has been reported by people with multiple myeloma, schizophrenia, breast cancer, preventive health care, high blood pressure (latest reports from 102,920 Agranulocytosis patients).

How to use the study?

Patients can bring a copy of the report to their healthcare provider to ensure that all drug risks and benefits are fully discussed and understood. It is recommended that patients use the information presented as a part of a broader decision-making process.

On Mar, 14, 2019

10 people who have Gallbladder Cancer Metastatic and Agranulocytosis are studied.

Number of reports submitted per year:

Would you have Agranulocytosis when you have Gallbladder cancer metastatic?

Gender of people who have Gallbladder Cancer Metastatic and experience Agranulocytosis *:

  • female: 40 %
  • male: 60 %

Age of people who have Gallbladder Cancer Metastatic and experience Agranulocytosis *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 0.0 %
  • 50-59: 40 %
  • 60+: 60 %

Top co-existing conditions for these people *:

  1. High Blood Pressure: 3 people, 30.00%
  2. Pain: 2 people, 20.00%
  3. Nausea (feeling of having an urge to vomit): 2 people, 20.00%
  4. Insomnia (sleeplessness): 2 people, 20.00%

Most common drugs for these people *:

  1. Sorafenib: 6 people, 60.00%
  2. Oxaliplatin: 4 people, 40.00%
  3. Capecitabine: 3 people, 30.00%
  4. Cisplatin: 3 people, 30.00%
  5. Neupogen: 3 people, 30.00%
  6. Gemcitabine: 3 people, 30.00%
  7. Levofloxacin: 2 people, 20.00%
  8. Epirubicin Hydrochloride: 2 people, 20.00%
  9. Furosemide: 2 people, 20.00%
  10. Ibuprofen: 2 people, 20.00%

Top symptoms for these people *:

  1. Abdominal Pain: 8 people, 80.00%
  2. Anaemia (lack of blood): 5 people, 50.00%
  3. Intestinal Obstruction: 5 people, 50.00%
  4. Malnutrition (condition that results from eating a diet in which certain nutrients are lacking): 3 people, 30.00%
  5. Ascites (accumulation of fluid in the abdominal cavity): 3 people, 30.00%
  6. Aspiration: 3 people, 30.00%
  7. Chills (felling of cold): 3 people, 30.00%
  8. Death: 3 people, 30.00%
  9. Fatigue (feeling of tiredness): 3 people, 30.00%
  10. Gallbladder Cancer Stage Iv (cancer has spread to a main blood vessel of the liver or to 2 or more nearby organs or areas other than the liver. cancer may have spread to nearby lymph nodes): 3 people, 30.00%

* Approximation only. Some reports may have incomplete information.

Do you have Agranulocytosis with Gallbladder cancer metastatic?

You are not alone:

Related studies

Drugs that are associated with Agranulocytosis
Agranulocytosis (2,585 drugs)
Other conditions that could cause Agranulocytosis
Agranulocytosis (2,770 conditions)
Browse all symptoms of Gallbladder cancer metastatic
a b c d e f g h i j k l m n o p q r s t u v w x y z

What would happen?

Predict new side effects and undetected conditions when you have Agranulocytosis and Gallbladder cancer metastatic

Recent updates

Recent general studies
Recent personal studies

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.